United States · Investor

Cormorant Asset Management

Last cheque observed Oct 2026; 176 cheques on record.

Email

Deploying nowNew fund $24M, Jun 2026Private equity

Series BSeries CVenturePharmaceuticalTherapeutics

Deploying now
83%of best year50cheques in 12 months, 176 on record
Since the last cheque2days00hrs00min00sec
Median round$102MRounds led1 of 176Sole investor5 roundsMostly inUnited States, 82%
Pitch Cormorant Asset Management

Cormorant Asset Management highlights

  1. 01

    50 cheques in the last 12 months

  2. 02

    Mostly Series B and Series C: 51% of its rounds

  3. 03

    Sole investor in 5 rounds, median $24M

What they do

Filed 4 private fund offerings with the SEC, the most recent in 2026-06From their own website
Type
Private equity (from a list, unverified)
Cheque size
Not stated
Sectors
PharmaceuticalTherapeutics
Based in
BOSTON, United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first176 appearances

  1. 2026

    41 rounds

  2. Oct
    Dren BioUS · Wowtale$350MWith 13 others
  3. Oct
    Star TherapeuticsUS · Pulse 2.0$200MWith 10 others
  4. Oct
    Zai LabCN · Pulse 2.0$250MWith 10 others
  5. Sept
    Tyra BiosciencesUS$400MWith 5 others
  6. Sept
    Orbis MedicinesVenture · DK$94MWith 4 others
  7. Aug
    Epicrispr BiotechnologiesSeries C · US$90MWith 3 others
  8. Jul
    Crystalys TherapeuticsSeries B · Frazier Life Sciences$130MWith 10 others
  9. Jul
    FORE BiotherapeuticsSeries D · US · Ventureburn$67MWith 15 others
  10. Jul
    ErascaUS$633MWith 4 others
  11. Jul
    Clearside BiomedicalDebt · US$3.0MWith 2 others
  12. Jul
    NeurogeneUS$125MWith 4 others
  13. Jul
    Cue BiopharmaUS$50MWith 1 other
  14. Jul
    FreenomeUS$240MWith 4 others
  15. Jun
    MoonLake ImmunotherapeuticsCH$200MWith 2 others
  16. Jun
    Tango TherapeuticsUS$600MWith 2 others
  17. Jun
    Triveni BioSeries C · US$65MWith 4 others
  18. Jun
    Enliven TherapeuticsUS$460MWith 3 others
  19. May
    Quince TherapeuticsUS$115MWith 1 other
  20. May
    Cabaletta BioUS$150MWith 4 others
  21. May
    Artiva BiotherapeuticsUS$300MWith 3 others
  22. May
    PharvarisCH$132MWith 4 others
  23. Apr
    Climb BioUS$110MWith 4 others
  24. Apr
    Spyre TherapeuticsUS$403MWith 3 others
  25. Apr
    Oruka TherapeuticsUS$700MWith 3 others
  26. Apr
    ValnevaFR$43MWith 4 others
  27. Apr
    GH ResearchIE$118MWith 4 others
  28. Apr
    Terremoto BiosciencesSeries C · US$108MWith 3 others
  29. Mar
    OnKure TherapeuticsUS$150MWith 4 others
  30. Mar
    Korro BioUS$85MWith 2 others
  31. Mar
    Ovid TherapeuticsUS$60MWith 3 others
  32. Mar
    Candid TherapeuticsVenture · US$505MWith 5 others
  33. Mar
    Tessera TherapeuticsVenture · USUndisclosedWith 3 others
  34. Mar
    Solid BiosciencesUS · Firms' own news pages$240MWith 8 others
  35. Feb
    Third Arc BioSeries A · US$52MWith 4 others
  36. Feb
    Beam TherapeuticsDebt · US$100MWith 5 others
  37. Feb
    Adlai Nortye$140MWith 2 others
  38. Jan
    Corvus PharmaceuticalsUS$201MWith 4 others
  39. Jan
    Parabilis MedicinesSeries F · US$305MWith 4 others
  40. Jan
    AlumisUS$345MWith 6 others
  41. Jan
    Monte Rosa TherapeuticsCH$300MWith 5 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration3 named

BCBihua ChenMs. Chen is the founder and Managing Member of the General Partner of the Issuer and the founder and portfolio manager of the Investment ManageriFiling they signed
CTCaleb TrippMr. Tripp is the Chief Financial Officer and Chief Operating Officer of both the General Partner and the Investment ManageriFiling they signed
JSJay ScollinsMr. Scollins is the Chief Financial Officer and Chief Operating Officer of both the General Partner and the Investment ManageriFiling they signed

We also hold 2 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

$3.8Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
Legal name
Cormorant Asset Management, LP
SEC number
CRD 167820

Who they invest alongside

The investors most often in the same rounds as Cormorant Asset Management. A count of rooms they were both in, not a relationship either has claimed.

RA Capital ManagementPrivate equity45rounds togetherJanus Henderson InvestorsPrivate equity39rounds togetherOrbiMedPrivate equity27rounds togetherPerceptive AdvisorsAsset manager26rounds togetherWellington ManagementVC firm25rounds togetherRedmile GroupVC firm19rounds togetherRTW Investments LLCGrowth equity18rounds togetherForesite CapitalPrivate equity17rounds togetherVivo CapitalPrivate equity14rounds togetherSamsara BioCapitalVC firm13rounds togetherARCH Venture PartnersVC firm11rounds togetherFidelityVC firm11rounds together

Recently backed

The latest companies Cormorant Asset Management put money into.

Dren Bio$350M · Oct 2026Star Therapeutics$200M · Oct 2026Tyra Biosciences$400M · Sept 2026Orbis Medicines$94M · Sept 2026Epicrispr Biotechnologies$90M · Aug 2026FORE Biotherapeutics$67M · Jul 2026

Quick answers about Cormorant Asset Management

What does Cormorant Asset Management invest in?

Cormorant Asset Management invests most often at Series B and Series C (51% of the rounds on record), in sectors such as Pharmaceutical and Therapeutics.

How active is Cormorant Asset Management?

176 investments on record, 50 of them in the last 12 months, and it led 1. The most recent was in Oct 2026.

What has Cormorant Asset Management invested in recently?

Its most recent investments on record: Dren Bio (Undisclosed round, Oct 2026), Star Therapeutics (Undisclosed round, Oct 2026) and Zai Lab (Undisclosed round, Oct 2026).

How big are Cormorant Asset Management's cheques?

The median round it joins is $102M.

Does Cormorant Asset Management lead rounds?

Sometimes: it led 1 of its 176 investments on record (1%).

Where does Cormorant Asset Management invest?

Most of the companies it backs are in the United States (82%) and Switzerland (8%).

Is Cormorant Asset Management investing now?

Yes: it is actively investing, with 50 investments in the last 12 months.

Who does Cormorant Asset Management invest alongside?

Most often RA Capital Management (45 rounds together), Janus Henderson Investors (39 rounds together) and OrbiMed (27 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it